A one-day accredited conference spotlighting the nutritional, physiological and ethical dimensions of GLP-1 and GIP therapies in obesity, type 2 diabetes and cardiometabolic health.
The Canadian Nutrition Society (CNS) is pleased to present the 2026 Thematic Conference “Beyond the Prescription: Single and Dual GLP-1/GIP Receptor Agonists, Nutrition and Health”, scheduled for January 30, 2026 at the DoubleTree by Hilton Toronto Downtown in Toronto (with virtual attendance options available).
This accredited program (recognised by the Royal College of Physicians and Surgeons of Canada – Section 1 and convertible to American Medical Association PRA Category 1 Credits
) offers up to 6.25 hours of continuing education.
The conference addresses the rapid adoption of incretin-based therapies (GLP-1 and GIP receptor agonists) that are now reshaping treatment of obesity and T2DM. Attendees will explore:
- The physiological, metabolic and nutritional implications of GLP-1/GIP therapies: appetite, weight loss, lean mass preservation and cardiometabolic effects.
- Practical strategies for diet quality, nutrient adequacy and managing weight rebound after therapy discontinuation.
- Ethical and practical aspects of equitable access, patient-centred care, and broader health effects beyond weight loss.
- Networking with leading researchers, clinicians and lived-experience speakers, plus panel discussions and workshops designed to spark collaboration and translate science into practice.
For full program details, registration (in-person and virtual), hotel booking and exhibitor information, please visit: https://thematic2026.cns-scn.ca
CNS Thematic Flyer 2026Download
Source: https://iuns.org/2025/11/beyond-the-pre ... nd-health/
